Psychedelic Medicine Podcast

Home
Psychedelic Medicine Podcast

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Psychedelic Medicine Podcast, Podcast, .

Our mission is to demystify and de-stigmatize psychedelic medicines by providing education on the latest research and current best-practice administration of these substances.

13/11/2025

In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.

Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected M**A for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation.

Link in the comments!

29/10/2025

In this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks shares findings from one of the first studies investigating psilocybin-assisted group therapy for depression, conducted in Oregon’s new legal psilocybin framework. He explains how the high cost and labor-intensive nature of psychedelic therapy inspired him to explore a group model that could make treatment more financially accessible while preserving - and even enhancing - its therapeutic potential.

Dr. Hicks describes the structure of the study and discusses how initial participant hesitancy about group work transformed into deep connection and shared healing. He also highlights the study’s significant reductions in depression scores, improvements across quality-of-life measures, and the potential for group-based approaches to pave the way toward insurance reimbursement and broader access to psychedelic care.

Link in the comments!

02/10/2025

In this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker shares insights from running the world’s largest randomized controlled trial on psilocybin microdosing for major depressive disorder. He explains the origins of microdosing research, from early anecdotes and surveys to his team’s carefully designed clinical study comparing psilocybin to placebo across different environments.

While participants in both groups reported significant improvements, the findings point to the powerful role of expectancy and placebo effects, alongside nuanced signals of cognitive shifts on measures like dysfunctional attitudes. Dr. Petranker emphasizes the importance of rigorous methodology, open science, and transparency in psychedelic research, while also acknowledging the stories of participants whose lives were positively impacted by study participation itself.

Link in the comments!

17/09/2025

In this encore episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don’t know about the role of the pineal gland and how this might relate to what is reported during near-death experiences.

He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use.

Link in the comments!

04/09/2025

In this episode Steven Zeiler, MD, PhD joins to discuss the promise of psychedelics for stroke healing. Dr. Zeiler explains that after a stroke, there is a natural but time-limited critical period during which the brain is highly plastic and capable of repairing motor function. His research, inspired by work on psychedelics reopening critical learning windows, shows in animal models that a single high dose of psychedelics combined with intensive rehabilitation can restore lost motor abilities even after recovery has plateaued. Throughout, Dr. Zeiler emphasizes that psilocybin itself doesn’t heal the brain directly but creates a window of heightened neuroplasticity that, when paired with targeted therapy, may dramatically improve recovery outcomes for stroke survivors.

Link in the comments!

20/08/2025

In this episode J. Ashley T. Booth, LCSW, MS joins to discuss the importance of long-term psychedelic integration. Ashley explores the nuances of psychedelic integration, discussing how this process can be supported through ongoing self-audits, somatic practices, and Internal Family Systems (IFS) work. She highlights the need to slow down, focus on one insight at a time, and anchor felt experiences into the body so they become lived behaviors rather than fleeting memories.

The discussion also addresses challenges such as insufficient integration, psychedelic narcissism, and the pressure to “fix” oneself. In closing, Ashley stresses that even years after a journey, integration is possible if one revisits experiences with intention, and she underscores the central role of supportive communities in sustaining lasting transformation

Link in the comments!

07/08/2025

In this episode, Dr. Genesee Herzberg joins to discuss the ways ketamine therapy can be combined with other healing modalities. Dr. Herzberg explains how somatic therapy, touch therapy, bodywork, and movement support trauma processing.

She also highlights the benefits of combining ketamine with acupuncture, craniosacral therapy, and functional medicine—including nutritional and hormonal assessments—to address physiological contributors to mental health. In closing, Dr. Herzberg emphasizes trauma-informed, team-based, and individualized approach to psychedelic healing, where ketamine acts as a bridge between psychological, somatic, and biomedical treatments.

Link in the comments!

24/07/2025

In this episode, Charmaine Husum joins to discuss how art therapy can be a powerful tool for psychedelic preparation and integration. Charmaine distinguishes between art as therapy and art therapy, emphasizing that the latter involves clinically informed, trauma-sensitive practices that externalize inner experiences to support healing.

She outlines structured protocols used before and after psychedelic experiences, including creating visual representations of inner strength, setting intentions, and integrating experiences through multi-phase art exercises. Throughout, Charmaine emphasizes choice, embodiment, and the historical roots of art in altered states, offering a rich alternative for those seeking non-verbal, experiential ways to work through trauma and transformation.

Link in the comments!

09/07/2025

In this conversation, Seth Mehr, MD outlines key risk categories for psilocybin therapy: medical conditions, medication interactions, and mental health history. He emphasizes the importance of individualized safety planning over binary yes/no decisions. Dr. Mehr discusses specific considerations such as cardiovascular issues, diabetes, serotonergic medications, substance use disorders, suicidal ideation, and family history of psychosis. The conversation also covers strategies for mitigating risk, including delaying treatment, contingency plans, improving support systems, and ensuring informed consent. Throughout, Dr. Mehr stresses a collaborative, nuanced approach that balances potential benefits with careful preparation and personalized care.

Link in the comments!

25/06/2025

In this episode, Monnica T. Williams, PhD, ABPP joins to discuss how psychedelics may help alleviate mental health impacts of racial trauma. Dr. Williams begins by highlighting the daily stress and trauma experienced by people of color, likening it to PTSD. She discusses a survey her team conducted which revealed that many people of color use psychedelics to manage racial trauma, showing significant reductions in stress, depression, and anxiety. Additionally, Dr. Williams emphasizes the importance of a safe environment and culturally competent therapists. In closing, she discusses ongoing research at this intersection and the need for more funding and awareness in this field.

Link in the comments!

12/06/2025

In this episode, Robin Carhart-Harris, PhD joins to elucidate the intersection of psychedelics and neuroplasticity. Dr. Carhart-Harris begins by discussing the impact of psychedelics on neuroplasticity and mental health. He explains neuroplasticity as the brain's ability to change, emphasizing its role in mood disorders and substance use and describes how stress atrophies the brain, leading to mental illness.

Dr. Carhart-Harris differentiates between neuroplasticity and neurogenesis, noting that while neurogenesis is limited in adults, neuroplasticity can be influenced by psychedelics like ketamine, psilocybin, and M**A. In closing, he also discusses the entropic brain hypothesis, suggesting that increased brain entropy leads to richer subjective experiences.

Link in the comments!

28/05/2025

In this episode, Dori Lewis, MA, MEd, LPC-S discusses the common myths and misconceptions surrounding psilocybin for healing.

The first myth that Dori addresses in this conversation is the idea that it is the psilocybin mushroom itself that does all the healing work. Contrary to this common misconception, Dori suggests that it is the client’s own initiative working in tandem with the mushroom that really spurs healing. She also emphasizes that there are not any set protocols for how often psilocybin should be taken for healing, instead suggesting that clients should be guided to attune to their own internal intuition to determine when a psilocybin journey may be particularly helpful.

Link in the comments!

Address

Website

http://plantmedicine.org/

Alerts

Be the first to know and let us send you an email when Psychedelic Medicine Podcast posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Psychedelic Medicine Podcast:

Shortcuts

Want your business to be the top-listed Media Company?

Country:

City: